Enzalutamide

Enzalutamide (formerly MDV3100) is an investigational compound in development for multiple stages of prostate cancer and for breast cancer.

Overview

Medivation and its collaboration partner, Astellas, is developing enzalutamide for multiple stages of prostate cancer and for breast cancer. The Company is conducting multiple trials of enzalutamide in prostate cancer disease states, including the Phase 3 PREVAIL trial in men with castration-resistant prostate cancer who have not received chemotherapy, and a Phase 2 trial of enzalutamide in breast cancer.